Posted by Michael Wonder on 03 Jul 2023
Genentech withdraws use of Gavreto in US for a type of thyroid cancer, says partner Blueprint
30 June 2023 - Genentech will withdraw Gavreto from use in the US for treating a type of thyroid cancer as it was not feasible for the Roche unit to pursue the drug for full approval, its partner Blueprint Medicines said on Friday.
The move comes after the Swiss drugmaker took an over $700 million impairment related to the drug last year.
